98%
921
2 minutes
20
Cerebrospinal fluid-based real-time quaking-induced conversion (CSF RT-QuIC) is currently the most prominent method for early detection of sporadic Creutzfeldt-Jakob disease (sCJD), the most common prion disease. CSF RT-QuIC delivers high sensitivity (>90%) and specificity (100%), which has been demonstrated by large ring-trial studies testing probable and definitive sCJD cohorts. Following the inclusion of CSF RT-QuIC in the revised European CJD Surveillance Network diagnostic criteria for sCJD, it has become a standard diagnostic procedure in many prion disease reference or surveillance centers around the world. In this study, we present the implementation of the second-generation CSF RT-QuIC (commonly known as Improved QuIC or IQ) at the Danish Reference Center for Prion Diseases (DRCPD). The method's sensitivity and specificity were evaluated and validated by analyzing 63 CSF samples. These 63 samples were also analyzed at the National CJD Research and Surveillance Unit (NCJDRSU), based at the University of Edinburgh, UK; analysis was carried out using the first generation or previous CSF RT-QuIC method (PQ). The sensitivity and specificity of PQ during tests at the NCJDRSU were 92% and 100%, respectively. Using these 63 CSF samples, the agreement between the two RT-QuIC generations at DRCPD and NCJDRSU prion laboratories was 100%.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094695 | PMC |
http://dx.doi.org/10.3390/ijms24076098 | DOI Listing |
J Neuropathol Exp Neurol
September 2025
Department of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia.
Prion diseases are rare neurodegenerative disorders that share misfolding of the normal cellular prion protein into disease-causing isoforms known as "prions" as the critical pathophysiological event. Definite diagnosis can only be achieved through neuropathological confirmation. The neuropathological features of prion disease are well described; however, some molecular subtypes are typified by characteristic neuropathological features that are subtle or absent.
View Article and Find Full Text PDFMov Disord
August 2025
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Background: Seed amplification assays (SAAs) for misfolded α-synuclein (syn) have shown inconsistent results in multiple system atrophy (MSA).
Objective: The objective of this study was to compare a novel syn SAA (synSAA) that distinguishes between Lewy body disease (LBD) and MSA syn-seeds (Amprion-SAA) with an LBD-specific synSAA (IRCCS Istituto delle Scienze Neurologiche di Bologna [ISNB]-SAA).
Methods: We applied both assays to cerebrospinal fluid samples from 114 patients with MSA, 49 patients with Parkinson disease (PD), 40 patients with progressive supranuclear palsy (PSP), and 46 controls.
BMC Geriatr
August 2025
Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
We report an atypical case of Creutzfeldt-Jakob Disease (CJD) mimicking Frontotemporal Dementia (FTD) in a 68-year-old male. The patient initially presented with an anxious-depressive syndrome, progressing over 29 months to include dysexecutive syndrome, stereotyped speech, inertia, social withdrawal, verbal fluency impairments, and marked dyspraxia. Diagnostic imaging revealed signal alterations on MRI, while CSF analysis showed elevated T-TAU, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) levels.
View Article and Find Full Text PDFCureus
June 2025
Neurology Institute, Doctors Hospital at Renaissance, McAllen, USA.
Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder instigated by the pleating of prion proteins. Most cases are sporadic, with no identifiable genetic or environmental trigger. This retrospective case series aims to bridge the current knowledge gap in regard to CJD in Hispanic populations.
View Article and Find Full Text PDFMol Neurodegener
July 2025
Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL, 32224, USA.
Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), is characterized by cognitive decline, sleep disturbances, motor dysfunction, and other debilitating clinical symptoms. Neuropathologically, LBD is characterized by the progressive accumulation of alpha-synuclein (aSYN) in vulnerable cellular populations in the brain. Diagnosing LBD is challenging due to the overlap of clinical symptoms with Alzheimer's disease (AD) and other neurodegenerative disorders with current diagnostic tools, including clinical examinations by specialized neurologists and brain imaging, limited by accessibility.
View Article and Find Full Text PDF